Key result
Immunisation of BALB/c mice with myosin purified from DCM-affected human hearts induced DCM-like myocardial damage, including myocytolysis, cardiosclerosis, and increased anti-myosin autoantibodies.
Absolute Event Rate: 6.76% vs 0.12%
p-value: p=<0.001
Immunization of BALB/c mice with myosin from DCM-affected human hearts, but not normal hearts, induces a DCM-like autoimmune myocardial injury, providing a novel experimental model for the disease.
Animal model implicates myosin autoimmunity in DCM; leaves open human relevance and therapeutic targeting.
Experimental model of autoimmune myosin-induced injury of BALB/c mouse myocardium, similar to human dilated cardiomyopathy (DCM), has been developed. The immunisation by myosin, purified from DCM-affected human heart initiated the following DCM-like myocardial damage: myocytolysis, cardiosclerosis, thinning of left ventricular wall, changes in cardiac actomyosin ATP-ase activity and increase of anti-myosin autoantibodies level.
No takes yet. Share an insight, caveat, or question.
Bobyk et al. (2007) studied Dilated cardiomyopathy (DCM). Immunisation with myosin purified from DCM-affected human heart (DVM) vs. Normal ventricle myosin (NVM) or Complete Freund's adjuvant (CFA) was evaluated on Relative volume of cardiomyocytes with myocytolysis at 21 days (p=<0.001). Immunisation of BALB/c mice with myosin purified from DCM-affected human hearts induced DCM-like myocardial damage, including myocytolysis, cardiosclerosis, and increased anti-myosin autoantibodies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: